I want to thank everybody who replied to my earlier question regarding a treatment decision. I got my PSMA results back today and it showed no spread or evidence of distant metastic disease. All seems contaimed to the Prostate. No nodal or bone spread.
However I do have Gleason 8 ( 3+5) and "likely" SVI according to earlier MRI. WIth this in mind i would think there is a 50/50 chance of a rising PSA after RALP. This was the path I was originally thinking of doing. If there is a 50/50 change I would need radiation after surgery, why not just go with radiation to start? That is my question. I am a veryhealthy and active 66 year old with no health issue but the PC.
My RO suggest 18-24 months of ADT, HDT Brachy and 5 weeks of beam radiation ( Proton or Photon). He said the results would be the same as doing surgery plus radiation. The Radiation route seems so much less invasive with lower SE.
Here is my initial MRI scan results below.
frankie08033
PROSTATE:
Size (AP x TRV x CC): 3.2 x 5.0 x 4.0 cm = 33.5 mL.
Post-biopsy hemorrhage: Not applicable.
Central gland enlargement (BPH): None.
Focal lesions - localization as follows:
Lesion: 1
Size: 1.8 x 1.2 x 1.5 cm (AP x TRV x CC), 5/23 and 9/16.
Location: Right base to midgland posterolateral peripheral zone
T2-weighted images: Score 5: Circumscribed, homogeneous moderate hypointense focus/mass greater than or equal to 1.5 cm in greatest dimension or definite extraprostatic extension/invasive behavior.
Diffusion-weighted images: Score 5: Focal markedly hypointense on ADC and markedly hyperintense on high b-value DWI, but greater than or equal to 1.5 cm in greatest dimension or definite extraprostatic extension/invasive behavior.
Dynamic post-contrast images: (+) Focal,and, earlier than or contemporaneous with enhancement of adjacent normal prostatic tissues, and, corresponds to a finding on T2-weighted and/or DWI.
PI-RADS Assessment Category: 5, Very high (clinically significant cancer highly likely).
Extra-prostatic extension (EPE): Overlying capsular bulging and mild irregularity with prominence of the neurovascular bundles (5/21 and 9/17).
Lesion: 2
Size: 5 x 5 x 8 mm (AP x TRV x CC), 9/16 and 5/23.
Location: Left base, lateral peripheral zone.
T2-weighted images: Score 4: Circumscribed, homogeneous moderate hypointense focus/mass confined to prostate and less than 1.5 cm in greatest dimension.
Diffusion-weighted images: Score 4: Focal markedly hypointense on ADC and markedly hyperintense on high b-value DWI; less than 1.5 cm in greatest dimension.
Dynamic post-contrast images: (+) Focal,and, earlier than or contemporaneous with enhancement of adjacent normal prostatic tissues, and, corresponds to a finding on T2-weighted and/or DWI.
PI-RADS Assessment Category: 4, High (clinically significant cancer likely).
Extra-prostatic extension (EPE): Overlying capsular irregularity without gross EPE.
Seminal vesicles: Ill-defined soft tissue along the course of the right seminal vesicles is concerning for tumoral invasion (4/15).
URINARY BLADDER: Trabeculated bladder with bladder diverticula measuring up to 3.2 x 1.7 cm in the left posterolateral bladder wall, suggestive of chronic bladder outlet obstruction.
LYMPH NODES: No pelvic lymphadenopathy.
BONES: No suspicious osseous lesion.
OTHER: Small fat-containing inguinal hernias bilaterally.
Note: Clinically significant cancer is defined on pathology/histology as Gleason score greater than or equal to 7, and/or volume of greater than or equal to 0.5 mL, and/or extraprostatic extension.
DynaCAD segmentation of the prostate and dominant nodule(s) was deferred as the patient has known clinically significant tumor. [DC0]
IMPRESSION:
1. Known clinically significant prostate cancer, with dominant peripheral zone PI-RADS 5 lesion in the right base-mid gland and PI-RADS 4 lesion in the left base.
2. Mild extraprostatic tumor extension on the right with likely neurovascular and invasion and mild right seminal vesicle invasion. Mild capsular irregularity on the left without gross extraprostatic extension. No pelvic lymphadenopathy or pelvic osseous metastatic disease.
3. Calculated prostate volume of 34 mL.